A Phase 3 interventional study of Idelalisib and Rituximab in Chronic Lymphocytic Leukemia, sponsored by Gilead Sciences. Completed at 106 sites in 18 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-03-10.
Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies testing idelalisib in Leukemia, Lymphocytic, Chronic, B-Cell — 1 open to participants now, 1 under way, none of them phase 3. idelalisib · Leukemia, Lymphocytic, Chronic, B-Cell.
Among the 25 studies testing idelalisib in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 2nd largest by enrollment, is one of 5 that started in 2012, is one of 8 in phase 3, and was the 8th registered.
2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 237 are open to participants now.
Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →1 of the 25 studies testing idelalisib in Leukemia, Lymphocytic, Chronic, B-Cell is open now, in 12 countries. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United States, Australia, Austria and 14 more countries
Ages 18+
By country, each count listing its studies:
idelalisib: first FDA approval 2014 (ZYDELIG), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 188 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 13 · Phase 3 8 · Phase 4 1
First in 2008; this study’s year is marked. 5 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 416 is above the median of 39 across 1,603 interventional studies indexed under Leukemia, Lymphocytic, Chronic, B-Cell.
Median enrollment 102 across the 25 interventional studies. Of the 22 that completed or were terminated, 21 (95%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 25 have an industry lead sponsor. The 7 most frequent:
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
36 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Gilead Sciences: none open now, none under way, none of them phase 3. Of 32 finished, 22 (69%) have results posted.
Among the 36 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Gilead Sciences, this one is the 2nd largest by enrollment of the 35 interventional ones that give a count, is one of 7 that started in 2012, is one of 9 in phase 3, and was the 14th registered.
Gilead Sciences’s Leukemia, Lymphocytic, Chronic, B-Cell studies by the year they started, since 1997.
None of the studies under way reaches primary completion within a year.
Among the 25 studies testing idelalisib in Leukemia, Lymphocytic, Chronic, B-Cell, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Gilead Sciences’s 36 in Leukemia, Lymphocytic, Chronic, B-Cell:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to evaluate the effect of the addition of idelalisib (formerly GS-1101) to bendamustine + rituximab (BR) on progression-free survival (PFS) in participants with previously treated chronic lymphocytic leukemia (CLL)
Key Inclusion Criteria:
Key Exclusion Criteria:
NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive idelalisib plus bendamustine and rituximab
Drug: Idelalisib · Drug: Rituximab · Drug: Bendamustine
Participants will receive placebo to match idelalisib plus bendamustine and rituximab
Drug: Rituximab · Drug: Bendamustine · Drug: Placebo to match idelalisib
Idelalisib 150 mg administered orally twice daily
Also known as: GS-1101, CAL-101, Zydelig®
Rituximab 375 mg/m\^2 on Day 1, then 500 mg/m\^2 every 28 days administered intravenously for a maximum of 6 infusions
Also known as: Rituxan®, MabThera
Bendamustine 70 mg/mg\^2/day on 2 consecutive days every 28 days administered intravenously for a maximum of 12 infusions
Also known as: Ribomustin, Treanda®
Placebo to match idelalisib administered orally twice daily
Progression-Free Survival (PFS)
PFS was defined as the interval from randomization to the earlier of the first documentation of definitive disease progression or death from any cause. PFS (months) = (minimum (date of disease progression, date of death) - date of randomization + 1)/30.4375.
Time frame: Up to 84 months
Overall Response Rate (ORR)
ORR was the percentage of participants who achieved a complete response (CR), CR with incomplete marrow recovery (CRi,) or partial response (PR) and maintained the response for at least 12 weeks. CR was defined as no lymphadenopathy, hepatomegaly, splenomegaly; normal complete blood count; confirmed by bone marrow aspirate \& biopsy. PR was defined as \>1 of the following criteria: a 50% decrease in peripheral blood lymphocytes, lymphadenopathy, liver size, spleen size; plus ≥ 1 of the following: ≥ 1500/μL absolute neutrophil count, \> 100000/μL platelets, \> 11.0 g/dL hemoglobin or 50% improvement for either of these parameters without transfusions or growth factors. CRi was defined as all criteria for CR met but with persistent anemia, thrombocytopenia, neutropenia or a hypocellular bone marrow.
Time frame: Up to 84 months
Lymph Node Response Rate
Lymph node response rate was defined as the percentage of participants who achieved a ≥ 50% decrease from baseline in the sum of the products of the greatest perpendicular diameters (SPD) of index lesions.
Time frame: Up to 84 months
Overall Survival
Overall survival (OS) was defined as the interval from randomization to death from any cause. Overall survival (months) = (date of death - date of randomization + 1)/30.4375.
Time frame: Up to 84 months
Complete Response Rate
Complete response (CR) rate was defined as the percentage of participants who achieved a CR.
Time frame: Up to 84 months
Participants were enrolled at a total of 110 sites in Australia, New Zealand, Europe, Asia and North America. The first participant was screened on 15 June 2012. The last study visit occurred on 10 June 2019.
| Milestone | Idelalisib + Bendamustine + Rituximab | Placebo + Bendamustine + Rituximab |
|---|---|---|
| Started | 207 | 209 |
| Long-term follow-up | 109 | 161 |
| Completed | 0 | 0 |
| Not completed | 207 | 209 |
| Withdrew: Progressive disease | 75 | 139 |
| Withdrew: Adverse event | 39 | 14 |
| Withdrew: Withdrawal by subject | 25 | 12 |
| Withdrew: Death | 19 | 15 |
| Withdrew: Physician decision | 13 | 18 |
| Withdrew: Study terminated by sponsor | 24 | 2 |
| Withdrew: Other reason not specified | 3 | 5 |
| Withdrew: Non-compliance with study drug | 6 | 1 |
| Withdrew: Other anticancer/experimental therapy | 2 | 2 |
| Withdrew: Lost to follow-up | 1 | 1 |
PFS was defined as the interval from randomization to the earlier of the first documentation of definitive disease progression or death from any cause. PFS (months) = (minimum (date of disease progression, date of death) - date of randomization + 1)/30.4375.
| months | Idelalisib + Bendamustine + Rituximab | Placebo + Bendamustine + Rituximab |
|---|---|---|
| Progression-Free Survival (PFS) | 21.8 (16.5 to 27.8) | 11.1 (8.9 to 11.1) |
ORR was the percentage of participants who achieved a complete response (CR), CR with incomplete marrow recovery (CRi,) or partial response (PR) and maintained the response for at least 12 weeks. CR was defined as no lymphadenopathy, hepatomegaly, splenomegaly; normal complete blood count; confirmed by bone marrow aspirate \& biopsy. PR was defined as \>1 of the following criteria: a 50% decrease in peripheral blood lymphocytes, lymphadenopathy, liver size, spleen size; plus ≥ 1 of the following: ≥ 1500/μL absolute neutrophil count, \> 100000/μL platelets, \> 11.0 g/dL hemoglobin or 50% improvement for either of these parameters without transfusions or growth factors. CRi was defined as all criteria for CR met but with persistent anemia, thrombocytopenia, neutropenia or a hypocellular bone marrow.
| percentage of participants | Idelalisib + Bendamustine + Rituximab | Placebo + Bendamustine + Rituximab |
|---|---|---|
| Overall Response Rate (ORR) | 70.0 (63.3 to 76.2) | 45.5 (38.6 to 52.5) |
Lymph node response rate was defined as the percentage of participants who achieved a ≥ 50% decrease from baseline in the sum of the products of the greatest perpendicular diameters (SPD) of index lesions.
| percentage of particpants | Idelalisib + Bendamustine + Rituximab | Placebo + Bendamustine + Rituximab |
|---|---|---|
| Lymph Node Response Rate | 96.9 (93.3 to 98.8) | 60.9 (53.7 to 67.8) |
Overall survival (OS) was defined as the interval from randomization to death from any cause. Overall survival (months) = (date of death - date of randomization + 1)/30.4375.
| months | Idelalisib + Bendamustine + Rituximab | Placebo + Bendamustine + Rituximab |
|---|---|---|
| Overall Survival | 56.2 (40.1 to NA) | 42.6 (35.3 to 54.8) |
Complete response (CR) rate was defined as the percentage of participants who achieved a CR.
| percentage of participants | Idelalisib + Bendamustine + Rituximab | Placebo + Bendamustine + Rituximab |
|---|---|---|
| Complete Response Rate | 4.3 (2.0 to 8.1) | 0.5 (0 to 2.6) |
Collected over First dose up to the last dose date plus 30 days (Up to approximately 67.7 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Idelalisib + Bendamustine + Rituximab | 89/207 (43%) | 152/207 (73.4%) | 199/207 (96.1%) |
| Placebo + Bendamustine + Rituximab | 106/209 (50.7%) | 94/209 (45%) | 196/209 (93.8%) |
| Event | Idelalisib + Bendamustine + Rituximab | Placebo + Bendamustine + Rituximab |
|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 45/207 | 10/209 |
| PneumoniaInfections and infestations | 38/207 | 16/209 |
| PyrexiaGeneral disorders | 25/207 | 11/209 |
| DiarrhoeaGastrointestinal disorders | 14/207 | 1/209 |
| SepsisInfections and infestations | 11/207 | 4/209 |
| NeutropeniaBlood and lymphatic system disorders | 9/207 | 3/209 |
| AnaemiaBlood and lymphatic system disorders | 8/207 | 5/209 |
| Lower respiratory tract infectionInfections and infestations | 7/207 | 5/209 |
| Urinary tract infectionInfections and infestations | 7/207 | 3/209 |
| Neutropenic sepsisInfections and infestations | 3/207 | 6/209 |
| Event | Idelalisib + Bendamustine + Rituximab | Placebo + Bendamustine + Rituximab |
|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 129/207 | 113/209 |
| DiarrhoeaGastrointestinal disorders | 89/207 | 47/209 |
| PyrexiaGeneral disorders | 78/207 | 55/209 |
| NauseaGastrointestinal disorders | 60/207 | 72/209 |
| AnaemiaBlood and lymphatic system disorders | 54/207 | 48/209 |
| CoughRespiratory, thoracic and mediastinal disorders | 52/207 | 47/209 |
| FatigueGeneral disorders | 45/207 | 52/209 |
| ThrombocytopeniaBlood and lymphatic system disorders | 41/207 | 46/209 |
| Infusion related reactionInjury, poisoning and procedural complications | 29/207 | 45/209 |
| Upper respiratory tract infectionInfections and infestations | 37/207 | 21/209 |
The intent-to-treat (ITT) Analysis Set included all participants randomized in the study regardless of whether study drug was administered and with treatment group designated according to initial randomization.
| Age, Continuous(years) | Idelalisib + Bendamustine + Rituximab | Placebo + Bendamustine + Rituximab | Total |
|---|---|---|---|
| Mean | 62 ± 9.2 | 63 ± 9.8 | 62 ± 9.5 |
| Sex: Female, Male(Participants) | Idelalisib + Bendamustine + Rituximab | Placebo + Bendamustine + Rituximab | Total |
|---|---|---|---|
| Female | 47 | 53 | 100 |
| Male | 160 | 156 | 316 |
| Race/Ethnicity, Customized(Participants) | Idelalisib + Bendamustine + Rituximab | Placebo + Bendamustine + Rituximab | Total |
|---|---|---|---|
| Race — White | 187 | 190 | 377 |
| Race — Black or African American | 6 | 4 | 10 |
| Race — Asian | 2 | 1 | 3 |
| Race — Other | 2 | 2 | 4 |
| Race — Not Permitted | 10 | 12 | 22 |
| Race/Ethnicity, Customized(Participants) | Idelalisib + Bendamustine + Rituximab | Placebo + Bendamustine + Rituximab | Total |
|---|---|---|---|
| Ethnicity — Hispanic or Latino | 4 | 5 | 9 |
| Ethnicity — Not Hispanic or Latino | 191 | 188 | 379 |
| Ethnicity — Not Permitted | 12 | 15 | 27 |
| Ethnicity — Missing | 0 | 1 | 1 |
| Region of Enrollment(Participants) | Idelalisib + Bendamustine + Rituximab | Placebo + Bendamustine + Rituximab | Total |
|---|---|---|---|
| Romania | 5 | 6 | 11 |
| Hungary | 24 | 20 | 44 |
| United States | 37 | 33 | 70 |
| Czechia | 9 | 5 | 14 |
| United Kingdom | 27 | 29 | 56 |
| Portugal | 1 | 4 | 5 |
| Russia | 22 | 14 | 36 |
| Spain | 14 | 18 | 32 |
| Greece | 1 | 1 | 2 |
| Canada | 0 | 3 | 3 |
| Turkey | 6 | 6 | 12 |
| Belgium | 3 | 7 | 10 |
| Ireland | 1 | 1 | 2 |
| Poland | 17 | 22 | 39 |
| Italy | 10 | 7 | 17 |
| Australia | 8 | 8 | 16 |
| France | 13 | 14 | 27 |
| Croatia | 5 | 9 | 14 |
| New Zealand | 4 | 2 | 6 |
Showing the first 100 of 106 sites across 18 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy.
Supporting information: Study protocol, Statistical analysis plan
Time frame: 18 months after study completion
Access criteria: A secured external environment with username, password, and RSA code.
Data sharing details ↗ · www.gilead.com
Ran from Jun 2012 to primary completion in Jun 2019, 83 months.
Of 57 industry-sponsored phase 3 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 73. This study's 83 months is above that.
Counting every sponsor, half of 83 studies reached it within 59 months; a quarter within 43 and three quarters within 76.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Idelalisib
Leukemia, Lymphocytic, Chronic, B-Cell →